Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline

75Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: To determine the population pharmacokinetic parameters of vancomycin in neonatal patients with a wide range of gestational age and birth weight, and subsequently to design an initial dosing schedule for vancomycin in neonates. Methods: Using nonlinear mixed-effects modelling (NONMEM VI), the pharmacokinetics of vancomycin were investigated in 70 neonates with postmenstrual age and body weight ranging 25.1-48.1 weeks and 0.7-3.7 kg, respectively. A one-compartment linear disposition model with zero order input and first-order elimination was used to describe the data. Nine demographic characteristics and 21 co-administered drugs were evaluated as covariates of clearance (CL) and distribution volume (Vd) of vancomycin. Results: Weight-normalized clearance of vancomycin was influenced by postmenstrual age (PMA) and co-administration of amoxicillin-clavulanic acid. Weight-normalized volume of distribution was influenced by co-administration of spironolactone. CL and Vd of the typical individual in this study population (PMA = 34.6 weeks, weight = 1.7 kg) were estimated to be 0.066 l h-1 kg-1 (95% CI 0.059, 0.073 l h-1 kg-1) and 0.572 l kg-1 (95% CI 0.505, 0.639 l kg-1), respectively. This model was used to predict a priori serum vancomycin concentrations in a validation group (n = 41), which were compared with observed concentrations to determine the predictive performance of the model. The 95% confidence interval of mean prediction error included zero for both peak and trough vancomycin concentrations. Conclusions: Postmenstrual age, co-administration of amoxicillin-clavulanic acid and spironolactone have a significant effect on the weight-normalized CL and Vd. An initial dosage guideline for vancomycin is proposed for preterm and full-term neonates, whereas the population pharmacokinetic model can be used for dosage individualization of vancomycin. © 2010 The Authors British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.

Cite

CITATION STYLE

APA

Marqués-Miñana, M. R., Saadeddin, A., & Peris, J. E. (2010). Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. British Journal of Clinical Pharmacology, 70(5), 713–720. https://doi.org/10.1111/j.1365-2125.2010.03736.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free